- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
Loading...
THE CLINICAL DEVELOPMENT OF MEK INHIBITORS MEK1 and MEK2 have key roles in tumorigenesis and, therefore, represent promising targets for cancer therapy; however, MEK1/2 inhibitors have been
shown to have efficacy in only a narrow range of cancer types, mainly tumours that harbour_BRAF_ or _NRAS_mutations. In this article, the clinical experience with MEK inhibitors to date is
reviewed, and potential approaches to overcoming therapeutic resistance and increasing the efficacy of treatment are discussed. * Yujie Zhao * Alex A. Adjei
